A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: Results of a prospective multicenter phase ii study in patients with follicular lymphoma

Annals of Oncology

Volumn 23, Issue 10, 2012, Pages 2687-2695

  Morschhauser, F ^a   Recher, C ^b   Milpied, N ^c   Gressin, R ^d   Salles, G ^e   Brice, P ^f   Vey, N ^g   Haioun, C ^h   Colombat, P ⁱ   Rossi, J F ^j   Deconinck, E ^k   Lazreg, F ^l   Bergougnoux, L ^l   Delsol, G ^b   Attal, M ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b CHU PURPAN   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d HÔPITAL MICHALLON   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g INSTITUT PAOLI CALMETTES   (France)

^h HENRI MONDOR HOSPITAL   (France)

ⁱ CHU BRETONNEAU   (France)

^j LAPEYRONIE HOSPITAL   (France)

^k UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^l Roche ^*  (France)

more..

Author keywords

Autologous stem cell transplantation; Follicular lymphoma; Minimal residual disease; Rituximab

Indexed keywords

DEXCHLORPHENIRAMINE; PARACETAMOL; RITUXIMAB;

ADULT; AGED; ARTHRALGIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CONTROL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; COURSE EVALUATION; DISEASE DURATION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MALE; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MULTICENTER STUDY; NEUTROPENIA; OPEN STUDY; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHINITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84867112110     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds202     Document Type: Article

References (57)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909-3918.
2. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16(8): 2780-2795.
3. Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-1423.
4. Herold M, Haas A, Srock S et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25: 1986-1992.
5. Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725-3732.
6. Salles G, Mounier N, De Guibert S et al. Final analysis of the GELA-GOELAMS FL2000 study with a 5-year follow-up. Blood 2007; 110: 792A.
7. Hunault-Berger M, Ifrah N, Solal-Celigny P. Intensive therapies in follicular non-Hodgkin lymphomas. Blood 2002; 100: 1141-1152.
8. Hiddemann W, Buske C, Dreyling M et al. Treatment strategies in follicular lymphomas: current status and future perspectives. J Clin Oncol 2005A; 23(26): 6394-6399.
9. Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin lymphoma. Ann Rev Med 2008; 59: 237-250.
10. Sebban C, Mounier N, Brousse N et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006; 108(8): 2540-2544.
11. Gyan E, Foussard C, Bertrand P et al. Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang (GOELAMS). High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood 2009; 113(5): 995-1001.
12. Salles G, Seymour JF, Offner F et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377(9759): 42-51.
13. Lenz G, Dreyling M, Schiegnitz E et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 2667-2674.
14. Buske C, Hoster E, Dreyling M et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate-or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006; 108(5): 1504-1508.
15. Buske C, Hoster E, Dreyling M et al. German Low-Grade Lymphoma Study Group. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 2009; 23(1): 153-161.
16. Sebban C, Brice P, Delarue R et al. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 2008; 26(21): 3614-3620.
17. Schouten HC, Qian W, Kvaloy S et al. High-dose therapy improves progressionfree survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21(21): 3918-3927.
18. Dreyling M. ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): v181-v183.
19. Tse WW, Lazarus HM, Van Besien K. Stem cell transplantation in follicular lymphoma: progress at last? Bone Marrow Transplant 2004; 34(11): 929-938.
20. Freedman AS, Neuberg D, Mauch P et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325-3333.
21. Apostolidis J, Gupta RK, Grenzelias D et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: longterm clinical and molecular follow-up. J Clin Oncol 2000; 18(3): 527-536.
22. Bowman A, Jones D, Medeiros LJ et al. Quantitative PCR detection of t(14;18) bcl-2/JH fusion sequences in follicular lymphoma patients. Comparison of peripheral blood and bone marrow aspirate samples. JMD 2004; 6: 4.
23. Hirt C, Dolken G. Quantitative detection of t(14;18)-positive cells in patients with follicular lymphoma before and after autologous bone marrow transplantation. Bone Marrow Transplant 2000; 25(4): 419-426.
24. Hirt C, Schüler F, Dölken G. Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab. Semin Cancer Biol 2003; 13(3): 223-231.
25. Dolken L, Schuler F, Dolken G. Quantitative detection of t(14;18)-positive cells by real-time quantitative PCR using fluorogenic probes. Biotechniques 1998; 25(6): 1058-1064.
26. Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101-106.
27. Rambaldi A, Lazzari M, Manzoni C et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002; 99(3): 856-862.
28. Anderson KC, Ritz J, Takvorian T et al. Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow. Blood 1987; 69: 597-604.
29. Ladetto M, De Marco F, Benedetti F et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008; 111(8): 4004-4013.
30. Galoin S, al Saati T, Schlaifer D et al. Oligonucleotide clonospecific probes directed against the junctional sequence of t(14;18): a new tool for the assessment of minimal residual disease in follicular lymphomas. Br J Haematol 1996; 94(4): 676-684.
31. Rauzy O, Galoin S, Chale JJ et al. Detection of t(14;18) carrying cells in bone marrow and peripheral blood from patients affected by non-lymphoid diseases. Mol Pathol 1998; 51(6): 333-338.
32. Al Saati T, Galoin S, Roda D et al. Detection of residual disease in follicular lymphomas using the PCR technique: importance of clono-specific probes. Bull Cancer 1998; 85(10): 847-854.
33. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
34. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
35. Mangel J, Buckstein R, Imrie K et al. Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation. Ann Oncol 2003; 14(5): 758-765.
36. Brugger W, Hirsch J, Grünebach F et al. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol 2004; 15(11): 1691-1698.
37. Woods A, Buckstein R, Mangel J et al. High-dose therapy/ASCT with rituximab for in-vivo purging and post-ASCT consolidation in relapsed follicular lymphoma achieves prolonged clinical and molecular remissions. Blood 2004; 104: 262a.
38. Neumann F, Harnsen S, Martin S et al. Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B cell non-Hodgkin's lymphoma. Ann Hematol 2006; 85: 530-534.
39. Darby AJ, Johnson PW. Molecular remission and non-Hodgkin's lymphoma. Best Pract Res Clin Haematol 2002; 15(3): 549-562.
40. Hirt C, Schüler F, Kiefer T et al. Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients. Br J Haematol 2008; 141(5): 631-640.
41. Dölken G, Dölken L, Hirt C et al. Age-dependent prevalence and frequency of circulating t(14;18)-positive cells in the peripheral blood of healthy individuals. J Natl Cancer Inst Monogr 2008; (39): 44-47.
42. Janz S, Potter M, Rabkin CS. Lymphoma-and leukemia-associated chromosomal translocations in healthy individuals. Genes Chromosomes Cancer 2003; 36(3): 211-223.
43. Dreyling M, Forstpointner R, Ludwig W et al. The addition of rituximab to fludarabine combination (R-FCM) significantly improves remission rates and overall survival in recurrent follicular as well as mantle cell lymphoma-follow-up of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) [abstract]. Ann Oncol. 2005;16: 110. Abstract #252.
44. Van Oers MH, Van Glabbeke M, Giurgea L et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010; 28(17): 2853-2858.
45. Pettengell R, Schmitz N, Gisselbrecht C et al. Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy. 2010 ASCO Annual Meeting. J Clin Oncol 2010; 28: 15s, (suppl; abstr 8005).
46. Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99(3): 754-758.
47. Cartron G, Watier H, Golay J et al. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104(9): 2635-2642.
48. Cartron G, Zhao-Yang L, Baudard M et al. Granulocyte-macrophage colonystimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. J Clin Oncol 2008; 26(16): 2725-2731.
49. Bosly AE, Staquet PJ, Doyen CM et al. Recombinant human interleukin-2 restores in vitro T-cell colony formation by peripheral blood mononuclear cells after autologous bone marrow transplantation. Exp Hematol 1987; 15(10): 1048-1054.
50. Roberts MM, To LB, Gillis D et al. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation. Bone Marrow Transplant 1993; 12(5): 469-475.
51. Ashihara E, Shimazaki C, Yamagata N et al. Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation: two-color flow cytometric analysis. Bone Marrow Transplant 1994; 13(4): 377-381.
52. Talmadge JE, Reed E, Ino K et al. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant 1997; 19(2): 161-172.
53. Guillaume T, Rubinstein DB, Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 1998; 92: 1471-1490.
54. Lindgren CG, Thompson JA, Robinson N et al. Interleukin-12 induced cytolytic activity in lymphocytes from recipients of autologous and allogeneic stem cell transplants. Bone Marrow Transplant 1997; 19(9): 867-873.
55. Mössner E, Brünker P, Moser S et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115(22): 4393-4402.
56. Hilchey SP, Hyrien O, Mosmann TR et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a 'vaccinal effect' of rituximab. Blood 2009; 113 (16): 3809-3812.
57. Abès R, Gélizé E, Fridman WH et al. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 2010; 116(6): 926-934.